RxDoctor Payments Data

Abigail Byrnes, MD

Hematology & Oncology · Corbin, KYNPI 1902902372

Payments from drug & device makers

$11,090in general payments, 2019–2025

Across 577 payments — averaging $19.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$963
  • Johnson & Johnson$944
  • AstraZeneca$734
  • Novartis$622
  • Pfizer$535
  • Astellas Pharma US Inc$516
  • plus $7K from 54 others

What the payments were for

  • Food & beverage$10,22592%
  • Education$8408%
  • Gifts$250%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck53$963
Johnson & Johnson38$944
AstraZeneca37$734
Novartis34$622
Pfizer36$535
Astellas Pharma US Inc21$516
Daiichi Sankyo Inc.24$444
E.r. Squibb & Sons, L.L.C.33$437
Amgen20$429
Regeneron Healthcare Solutions, Inc.17$377
Gilead(2 entities)16$361
AbbVie19$355
Sanofi16$338
Incyte Corporation14$312
Bristol Myers Squibb15$286
Genentech USA, Inc.18$281
GSK10$196
Seagen Inc.10$189
Karyopharm Therapeutics Inc.9$173
Cumberland Pharmaceuticals, Inc.7$146
Bayer9$144
Genmab U.S., Inc.7$134
Array Biopharma Inc9$132
Pharmacosmos Therapeutics Inc.7$115
Exelixis Inc.3$115
AVEO Pharmaceuticals, Inc.7$114
Coherus Oncology, Inc.5$108
Takeda Pharmaceuticals U.S.A., Inc.4$103
Stemline Therapeutics Inc.4$97
Jazz Pharmaceuticals Inc.5$95
EMD Serono, Inc.3$90
Lilly USA, LLC5$87
Taiho Oncology, Inc.5$75
Pharmacyclics LLC, An Abbvie Company5$73
Progenics Pharmaceuticals, Inc.3$73
Kyowa Kirin, Inc.3$61
Ipsen Biopharmaceuticals, Inc3$58
Sobi, Inc2$51
Boehringer Ingelheim3$48
Sun Pharmaceutical Industries Inc.2$45
Verastem, Inc.2$44
Beone Medicines USA, Inc.1$37
ADC Therapeutics America, Inc.2$37
Beigene USA, Inc.2$35
Morphosys, US Inc.2$33
Caris MPI, Inc.2$33
Puma Biotechnology, Inc.2$32
Rigel Pharmaceuticals, Inc.2$31
Clovis Oncology, Inc.2$31
Tempus AI, Inc1$29
Tesaro, Inc.2$28
Advanced Accelerator Applications2$26
Eisai Inc.2$25
Tosoh Bioscience, Inc.1$25
Pharmaessentia USA Corporation1$20
Agios Pharmaceuticals, Inc.1$20
Blueprint Medicines Corporation1$20
Spectrum Pharmaceuticals Inc.1$19
Foundation Medicine, Inc.1$18
Iovance Biotherapeutics, Inc.1$17

How this compares

$11,090 in reported general payments places this provider in the 50th percentile of 143 hematology & oncology providers in Kentucky.

See all hematology & oncology providers in Kentucky

Medicare billing

Part B allowed, 2024
$55,692
Medicare patients
149
Services billed
560

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib13$199,350
JakafiRuxolitinib Phosphate12$198,606
CalquenceAcalabrutinib Maleate12$184,783
VerzenioAbemaciclib12$173,777
Abiraterone Acetate38$49,407
VotrientPazopanib Hcl12$37,246
EliquisApixaban46$34,923
Ondansetron Hcl110$20,951
Xtampza ErOxycodone Myristate23$14,722
Oxycodone Hcl88$3,416
Morphine Sulfate ErMorphine Sulfate71$3,159
Dronabinol18$2,978
Anastrozole200$2,827
Dexlansoprazole DrDexlansoprazole14$2,053
Tamoxifen Citrate56$1,329

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Pharmacyclics LLC, An Abbvie CompanyImbruvica$73$199,35013 claims
Incyte CorporationJakafi$312$198,60612 claims
AstraZenecaCalquence$734$184,78312 claims
Lilly USA, LLCVerzenio, Olanzapine$87$173,86254 claims
NovartisVotrient$622$37,24612 claims
PfizerEliquis$535$34,92346 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 143 hematology & oncology providers in Kentucky.

Other hematology & oncology in Corbin

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →